Trial Profile

A Phase 2a Randomized, Observer-blind, Placebo-controlled, Dosage Optimization, Multi-center Clinical Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Adults 60 to 85 Years of Age

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IVX-A12 (Primary) ; MF 59
Indications Metapneumovirus infections; Respiratory syncytial virus infections
Focus Adverse reactions; Pharmacodynamics; Proof of concept
Sponsors Icosavax

16 Oct 2024 According to AstraZeneca media release, data from this trial will be presented at IDWeek 2024
10 Apr 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
10 Apr 2024 Planned primary completion date changed from 10 May 2024 to 5 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com